Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial

Affiliations

¹ The Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
² Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
³ Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals, Nottingham, UK.

Editorial

John K Field et al. Transl Lung Cancer Res. 2018 Apr.

. 2018 Apr;7(Suppl 2):S114-S116.

doi: 10.21037/tlcr.2018.03.12.

¹ The Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
² Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
³ Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals, Nottingham, UK.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, Liu G, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrowes P, MacEachern P, Urbanski S, Sin DD, Tan WC, Leighl NB, Shepherd FA, Evans WK, Tsao MS, Lam S; PanCan Study Team. Tammemagi MC, et al. Lancet Oncol. 2017 Nov;18(11):1523-1531. doi: 10.1016/S1470-2045(17)30597-1. Epub 2017 Oct 18. Lancet Oncol. 2017. PMID: 29055736

1. National Lung Screening Trial Research Team , Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed
1. Katki HA, Kovalchik SA, Berg CD, et al. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. JAMA 2016;315:2300-11. 10.1001/jama.2016.6255 - DOI - PMC - PubMed
1. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014;371:1793-802. 10.1056/NEJMoa1312547 - DOI - PMC - PubMed
1. USPSTF. Lung Cancer Screening. Available online: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummary...
1. Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling [the Pan-Canadian Early Detection of Lung Cancer (PanCan) study]: a single-arm, prospective study. Lancet Oncol 2017;18:1523-31. 10.1016/S1470-2045(17)30597-1 - DOI - PubMed